Commercial Roche partners with Diabeloop to integrate automated insulin delivery

Roche partners with Diabeloop to integrate automated insulin delivery


As part of the deal, users will be able to integrate Roche’s Accu-Chek Insights insulin pump with the Diabeloop monitoring system.

Typically, hybrid systems are made up of a continuous glucose monitor, an insulin pump, and a glucose-detecting algorithm.

The Diabeloop system uses an algorithm to continuously monitor insulin levels and data.

In 2018, the Lancet published an investigative study that found the hybrid closed-loop demonstrated improved glucose control and lower risk of hypoglycemia compared to those managing their glucose levels with an insulin pump and CGM. “Diabetes management is complex and personal, and achieving therapy goals is an ongoing challenge. The integration of the Accu-Chek Insight insulin pump into an AID system creates new opportunities to lower the burden of constant insulin dose adjustment for people with diabetes,” Marcel Gmuender, head of Roche Diabetes Care, said in a statement.

Medtronic’s MiniMed 770G System landed FDA clearance in 2020 for its hybrid closed-loop system, which marked the first time an automated insulin-delivery system was greenlighted for young children with Type 1 diabetes.

Read full article here

Latest news

AstraZeneca and RQ Biotech enter into licensing agreement to develop antibodies against COVID-19

UK-based startup and British-Swedish pharma giant AstraZeneca have signed a licensing agreement amounting to over $150 million....

Kelun sells cancer drug development rights to Merck in a deal worth $1.4 billion

United States-based Merck & Co has made an addition to its cancer-fighting drugs after entering into a...

German Pharmaceutical and Medical Cannabis Products Distributor to be acquired by Franchise Global Health

The projected outcome of this acquisition is a boost in operations and the initiation of collaborations in...
- Advertisement -

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you